Primary Insulin-like Growth Factor-1 Deficiency

Also known as: Primary insulin like growth factor-1 deficiency

Drug	Drug Name	Drug Description
DB01277	Mecasermin	A recombinant insulin-like growth factor-1 used for the long-term treatment of growth failure in pediatric patients with primary IGF-1 deficiency or with growth hormone gene deletion due to the development of neutralizing antibodies to GH.
DB14751	Mecasermin rinfabate	Mecasermin rinfabate was approved for treatment of severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH) ....

Drug	Drug Name	Target	Type
DB01277	Mecasermin	Insulin-like growth factor 1 receptor	target
DB01277	Mecasermin	Insulin-like growth factor-binding protein 3	target
DB01277	Mecasermin	Insulin receptor	target
DB01277	Mecasermin	Cation-independent mannose-6-phosphate receptor	target
DB01277	Mecasermin	Insulin-like growth factor-binding protein 3	carrier
DB01277	Mecasermin	Insulin-like growth factor-binding protein complex acid labile subunit	carrier
DB01277	Mecasermin	Insulin-like growth factor-binding protein 1	carrier
DB01277	Mecasermin	Insulin-like growth factor-binding protein 2	carrier
DB01277	Mecasermin	Insulin-like growth factor-binding protein 4	carrier
DB01277	Mecasermin	Insulin-like growth factor-binding protein 5	carrier
DB01277	Mecasermin	Insulin-like growth factor-binding protein 6	carrier
DB14751	Mecasermin rinfabate	Insulin-like growth factor 1 receptor	target
DB14751	Mecasermin rinfabate	Insulin receptor	target
DB14751	Mecasermin rinfabate	Cation-independent mannose-6-phosphate receptor	target

Drug	Drug Name	Phase	Status	Count
DB01277	Mecasermin	Not Available	Terminated	1